{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 139,
  "pageCount": 366,
  "prevPage": 138,
  "nextPage": 140,
  "slideType": "preempt_rebuttal",
  "function": "preempt_rebuttal",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a direct excerpt from a package insert to support the argument that dose reduction is required due to drug interactions.",
  "elementsJson": [
    "paragraph",
    "data_table",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/139",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-139",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "As we shall show, danger due to pitolisant’s drug-drug interactions is inevitable and unavoidable, as it interacts strongly with medications like SSRI’s and other antidepressants that are widely prescribed for narcolepsy and cataplexy.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9cd4-9e45e4ddde64",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.43
      },
      "kind": "list",
      "text": "Strong CYP2D6 Inhibitors: Maximum recommended dosage is 17.8 mg once daily (2.4, 7.1)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d319d37-1464-4d6c-8dc3-882d398a5b18",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "CYP2D6 safety issues are not only triggered by genetically poor metabolizers, but also by those simultaneously taking other drugs than inhibit CYP2D6. The label therefore has a separate section for CYP2D6 inhibition due to drug-drug interactions, and once again recommends half the regular dose in this case. As we shall show, danger due to pitolisant’s drug-drug interactions is inevitable and unavoidable, as it interacts strongly with medications like SSRI’s and other antidepressants that are widely prescribed for narcolepsy and cataplexy.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "245be8d9-0255-409e-a6a7-b275b12ef7ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Concomitant administration of WAKIX with strong CYP2D6 inhibitors increases pitolisant exposure by 2.2-fold. — WAKIX Package Insert",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9cd4-a07e9e3ca7aa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.45,
        "x": 0.07,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Source: https://www.wakix.com/assets/pdf/WAKIX__pitolisant__tablets_PI_Dec_2022.pdf",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8669c46-edc8-48a5-8718-d40742799fad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.77,
        "x": 0.08,
        "y": 0.58
      },
      "kind": "table",
      "text": "Table 2: Clinically Significant Drug Interactions with WAKIX. Effect of Other Drugs on WAKIX. Strong CYP2D6 Inhibitors. Clinical Implication: Concomitant administration of WAKIX with strong CYP2D6 inhibitors increases pitolisant exposure by 2.2-fold. Prevention or Management: Reduce the dose of WAKIX by half.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5f046a6-75cb-4783-a4d9-85932ee31f5c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.86,
        "x": 0.07,
        "y": 0.34
      },
      "kind": "title",
      "text": "Pitolisant package insert and full prescribing information, excerpts – CYP2D6 dose adjustments due to potential drug-drug interactions",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "deb3cccf-5dc2-4280-913d-cf1851a70a13",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "019af6be-12c1-4fb7-9b5d-808cac974c56",
      "evidence": "The slide includes a table of clinically significant drug interactions.",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}